Brian Wojeck, MD, MPH
Assistant Professor of Medicine (Endocrinology)
Research & Publications
Biography
News
Coauthors
Selected Publications
- Chapter 35 Diseases of the pituitary glandWojeck B, Kryger M. Chapter 35 Diseases of the pituitary gland. 2024, 374-378.e1. DOI: 10.1016/b978-0-323-65403-6.00044-5.
- Role of metformin in the management of type 2 diabetes: recent advances.Gonzalez-Lopez C, Wojeck B. Role of metformin in the management of type 2 diabetes: recent advances. Polish Archives Of Internal Medicine 2023, 133 PMID: 37317976, DOI: 10.20452/pamw.16511.
- Polysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study.Wojeck B, Inzucchi S, Qin L, Yaggi H. Polysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study. Journal Of Clinical Sleep Medicine 2023, 19: 703-710. PMID: 36689314, PMCID: PMC10071389, DOI: 10.5664/jcsm.10414.
- Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialWojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing 2022, 27: 669-672. PMID: 35596030, PMCID: PMC10212814, DOI: 10.1007/s11325-022-02594-2.
- Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study.Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18: 2067-2078. PMID: 34185617, PMCID: PMC8641817, DOI: 10.1513/annalsats.202012-1556oc.
- Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors.Wojeck BS, Inzucchi SE. Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors. Diabetes Spectrum 2021, 34: 235-242. PMID: 34511849, PMCID: PMC8387615, DOI: 10.2337/ds20-0070.
- Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015Neeland IJ, Kasai T, Inzucchi SE, Wojeck BS, Yaggi HK, Johansen OE. Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015. Diabetes Care 2021, 44: e137-e138. PMID: 34016610, PMCID: PMC8247494, DOI: 10.2337/dci21-0009.
- Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 DiabetesDing Q, Qin L, Wojeck B, Inzucchi S, Ibrahim A, Bravata D, Strohl K, Yaggi H, Zinchuk A. Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes. 2021, a4679-a4679. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4679.
- Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trialYaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41 DOI: 10.1093/ehjci/ehaa946.2883.
- The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME TrialNeeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020, 43: 3007-3015. PMID: 33004464, PMCID: PMC7770278, DOI: 10.2337/dc20-1096.